Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors

Massimo Tempestilli, Elisa Gentilotti, Chiara Tommasi, Emanuele Nicastri, Federico Martini, Pasquale De Nardo, Pasquale Narciso, Leopoldo P. Pucillo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

It has been shown that P-glycoprotein (P-gp) can greatly affect the cell uptake of antiretroviral drugs, thus hampering their access to HIV-1 replication sites. Lymphocytes are important sites of replication of HIV and target of other drugs, modification on these cells of P-gp could have an effect on pharmacokinetic of antiretrovirals and drug substrates. Blood samples from 16 healthy volunteers were used to determine the expression of P-gp on total, T and T helper lymphocytes after exposure to darunavir, a second generation protease inhibitor, and raltegravir, the first approved integrase inhibitor. Moreover, the effect of the drugs on P-gp functional activity was also studied by the rhodamine-123 efflux test. Darunavir, but not raltegravir, exposure caused a moderate, dose-dependent increment in P-gp expression in total, T and T helper lymphocytes, as demonstrated by the relative frequency of P-gp + cells and by the amount of P-gp molecules present on cell surface. Functionally, incubation with darunavir led to a marked inhibition of P-gp activity measured by the efflux of rhodamine-123 similar to that observed by verapamil, a specific P-gp inhibitor. Raltegravir was not able to modify the efflux of rhodamine-123 level. Data show that darunavir, unlike raltegravir, may modify the expression and functionality of P-gp on human lymphocytes, thus leading to potential changes in intracellular concentrations of darunavir in patients treated with other drugs substrate of P-gp and vice versa. Our study highlights the need for studies on drug interactions via the P-gp modulation mechanism, especially with the current multi-drug regimens.

Original languageEnglish
Pages (from-to)492-497
Number of pages6
JournalInternational Immunopharmacology
Volume16
Issue number4
DOIs
Publication statusPublished - 2013

Fingerprint

P-Glycoprotein
Tissue Donors
Lymphocytes
Rhodamine 123
Therapeutics
Pharmaceutical Preparations
Helper-Inducer T-Lymphocytes
In Vitro Techniques
Darunavir
Raltegravir Potassium
Integrase Inhibitors
Verapamil
Protease Inhibitors
Drug Interactions
HIV-1
Healthy Volunteers
Pharmacokinetics
HIV

Keywords

  • Darunavir
  • Drug interaction
  • HIV
  • Lymphocyte
  • P-glycoprotein
  • Raltegravir

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

@article{a79fa0f84500492ea7ef9d330d93695a,
title = "Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors",
abstract = "It has been shown that P-glycoprotein (P-gp) can greatly affect the cell uptake of antiretroviral drugs, thus hampering their access to HIV-1 replication sites. Lymphocytes are important sites of replication of HIV and target of other drugs, modification on these cells of P-gp could have an effect on pharmacokinetic of antiretrovirals and drug substrates. Blood samples from 16 healthy volunteers were used to determine the expression of P-gp on total, T and T helper lymphocytes after exposure to darunavir, a second generation protease inhibitor, and raltegravir, the first approved integrase inhibitor. Moreover, the effect of the drugs on P-gp functional activity was also studied by the rhodamine-123 efflux test. Darunavir, but not raltegravir, exposure caused a moderate, dose-dependent increment in P-gp expression in total, T and T helper lymphocytes, as demonstrated by the relative frequency of P-gp + cells and by the amount of P-gp molecules present on cell surface. Functionally, incubation with darunavir led to a marked inhibition of P-gp activity measured by the efflux of rhodamine-123 similar to that observed by verapamil, a specific P-gp inhibitor. Raltegravir was not able to modify the efflux of rhodamine-123 level. Data show that darunavir, unlike raltegravir, may modify the expression and functionality of P-gp on human lymphocytes, thus leading to potential changes in intracellular concentrations of darunavir in patients treated with other drugs substrate of P-gp and vice versa. Our study highlights the need for studies on drug interactions via the P-gp modulation mechanism, especially with the current multi-drug regimens.",
keywords = "Darunavir, Drug interaction, HIV, Lymphocyte, P-glycoprotein, Raltegravir",
author = "Massimo Tempestilli and Elisa Gentilotti and Chiara Tommasi and Emanuele Nicastri and Federico Martini and {De Nardo}, Pasquale and Pasquale Narciso and Pucillo, {Leopoldo P.}",
year = "2013",
doi = "10.1016/j.intimp.2013.05.003",
language = "English",
volume = "16",
pages = "492--497",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors

AU - Tempestilli, Massimo

AU - Gentilotti, Elisa

AU - Tommasi, Chiara

AU - Nicastri, Emanuele

AU - Martini, Federico

AU - De Nardo, Pasquale

AU - Narciso, Pasquale

AU - Pucillo, Leopoldo P.

PY - 2013

Y1 - 2013

N2 - It has been shown that P-glycoprotein (P-gp) can greatly affect the cell uptake of antiretroviral drugs, thus hampering their access to HIV-1 replication sites. Lymphocytes are important sites of replication of HIV and target of other drugs, modification on these cells of P-gp could have an effect on pharmacokinetic of antiretrovirals and drug substrates. Blood samples from 16 healthy volunteers were used to determine the expression of P-gp on total, T and T helper lymphocytes after exposure to darunavir, a second generation protease inhibitor, and raltegravir, the first approved integrase inhibitor. Moreover, the effect of the drugs on P-gp functional activity was also studied by the rhodamine-123 efflux test. Darunavir, but not raltegravir, exposure caused a moderate, dose-dependent increment in P-gp expression in total, T and T helper lymphocytes, as demonstrated by the relative frequency of P-gp + cells and by the amount of P-gp molecules present on cell surface. Functionally, incubation with darunavir led to a marked inhibition of P-gp activity measured by the efflux of rhodamine-123 similar to that observed by verapamil, a specific P-gp inhibitor. Raltegravir was not able to modify the efflux of rhodamine-123 level. Data show that darunavir, unlike raltegravir, may modify the expression and functionality of P-gp on human lymphocytes, thus leading to potential changes in intracellular concentrations of darunavir in patients treated with other drugs substrate of P-gp and vice versa. Our study highlights the need for studies on drug interactions via the P-gp modulation mechanism, especially with the current multi-drug regimens.

AB - It has been shown that P-glycoprotein (P-gp) can greatly affect the cell uptake of antiretroviral drugs, thus hampering their access to HIV-1 replication sites. Lymphocytes are important sites of replication of HIV and target of other drugs, modification on these cells of P-gp could have an effect on pharmacokinetic of antiretrovirals and drug substrates. Blood samples from 16 healthy volunteers were used to determine the expression of P-gp on total, T and T helper lymphocytes after exposure to darunavir, a second generation protease inhibitor, and raltegravir, the first approved integrase inhibitor. Moreover, the effect of the drugs on P-gp functional activity was also studied by the rhodamine-123 efflux test. Darunavir, but not raltegravir, exposure caused a moderate, dose-dependent increment in P-gp expression in total, T and T helper lymphocytes, as demonstrated by the relative frequency of P-gp + cells and by the amount of P-gp molecules present on cell surface. Functionally, incubation with darunavir led to a marked inhibition of P-gp activity measured by the efflux of rhodamine-123 similar to that observed by verapamil, a specific P-gp inhibitor. Raltegravir was not able to modify the efflux of rhodamine-123 level. Data show that darunavir, unlike raltegravir, may modify the expression and functionality of P-gp on human lymphocytes, thus leading to potential changes in intracellular concentrations of darunavir in patients treated with other drugs substrate of P-gp and vice versa. Our study highlights the need for studies on drug interactions via the P-gp modulation mechanism, especially with the current multi-drug regimens.

KW - Darunavir

KW - Drug interaction

KW - HIV

KW - Lymphocyte

KW - P-glycoprotein

KW - Raltegravir

UR - http://www.scopus.com/inward/record.url?scp=84878449782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878449782&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2013.05.003

DO - 10.1016/j.intimp.2013.05.003

M3 - Article

C2 - 23707228

AN - SCOPUS:84878449782

VL - 16

SP - 492

EP - 497

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 4

ER -